Eur Heart J:糖尿病对肥厚型心肌病临床表型的影响

2018-10-28 xing.T MedSci原创

由此可见,患有糖尿病的肥厚型心肌病患者年龄较大,心血管风险较高。由于舒张功能障碍,他们具有较低的运动功能,以及会出现较多的心衰症状。

糖尿病(DM)加重了缺血性和高血压性心脏病的临床特征,并使心力衰竭患者的预后恶化。肥厚型心肌病(HCM)和糖尿病在老年患者中共存相当普遍,但是DM对HCM临床表型的影响尚不清楚。近日,血管领域权威杂志Eur Heart J上发表了一篇研究文章,研究人员试图描述DM患者心力衰竭的主要特征是否独立存在于HCM中。

研究人员回顾了来自西班牙和以色列两个三级医疗中心的937名年龄超过40岁且确诊为HCM患者的临床特征,还分析了与294名患者相匹配的倾向评分

该研究的队列纳入了102名(8.7%)患有糖尿病的HCM患者。DM患者在诊断时年龄较大{中位数为56 [四分位数范围(IQR)为47-67] vs. 53(IQR为43-63),P=0.02}并且合并症患病率较高。合并有DM的肥厚型心肌病患者的舒张功能障碍、肺动脉高压、显著的二尖瓣关闭不全和起搏器植入的患病率较高。合并DM的肥厚型心肌病患者具有较高的纽约心功能(NYHA)分级(P<0.001)和较低的运动能力[7.0METS(IQR为5.0-10.0) vs. 9.0METS(IQR为6.6-11.0),P=0.002]。这些发现与年龄、性别、原籍国、高血压和冠状动脉疾病无关。糖尿病患者具有显著较高的15年死亡率(22% vs. 15%,P=0.03),但是心源性猝死、适当植入心律转复除颤器治疗或心脏移植无差异。

由此可见,患有糖尿病的肥厚型心肌病患者年龄较大,血管风险较高。由于舒张功能障碍,他们具有较低的运动功能,以及会出现较多的心衰症状。

原始出处:

Yishay Wasserstrum.et al. The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy. Eur Heart J.2018. https://doi.org/10.1093/eurheartj/ehy625

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1356976, encodeId=46ef13569e6b9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487151, encodeId=7c9b148e15123, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535195, encodeId=be35153519592, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562993, encodeId=cf06156299330, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622353, encodeId=4a7a1622353c1, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041972, encodeId=4d5810419e20c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 28 20:28:00 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
    2018-10-30 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1356976, encodeId=46ef13569e6b9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487151, encodeId=7c9b148e15123, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535195, encodeId=be35153519592, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562993, encodeId=cf06156299330, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622353, encodeId=4a7a1622353c1, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041972, encodeId=4d5810419e20c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 28 20:28:00 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1356976, encodeId=46ef13569e6b9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487151, encodeId=7c9b148e15123, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535195, encodeId=be35153519592, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562993, encodeId=cf06156299330, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622353, encodeId=4a7a1622353c1, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041972, encodeId=4d5810419e20c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 28 20:28:00 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
    2018-10-30 tastas
  4. [GetPortalCommentsPageByObjectIdResponse(id=1356976, encodeId=46ef13569e6b9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487151, encodeId=7c9b148e15123, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535195, encodeId=be35153519592, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562993, encodeId=cf06156299330, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622353, encodeId=4a7a1622353c1, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041972, encodeId=4d5810419e20c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 28 20:28:00 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
    2018-10-30 slcumt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1356976, encodeId=46ef13569e6b9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487151, encodeId=7c9b148e15123, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535195, encodeId=be35153519592, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562993, encodeId=cf06156299330, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622353, encodeId=4a7a1622353c1, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041972, encodeId=4d5810419e20c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 28 20:28:00 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1356976, encodeId=46ef13569e6b9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487151, encodeId=7c9b148e15123, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535195, encodeId=be35153519592, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562993, encodeId=cf06156299330, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622353, encodeId=4a7a1622353c1, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Oct 30 08:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041972, encodeId=4d5810419e20c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 28 20:28:00 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
    2018-10-28 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Prostate Cancer P D:他汀类药物能够减少经历雄激素阻断治疗糖尿病患者的痴呆风险

雄激素阻断治疗(ADT)已经被报道可以增加痴呆的风险,而他汀类药物的使用可以减少痴呆的风险。最近,有研究人员在接受ADT的2型糖尿病(T2DM)患者中,调查了他汀类药物的使用和痴呆之间的相关性。研究总共包括了在1998年到2013年之间新诊断为PCa的9855名T2DM患者,其中5427名患者因PCa接受了雄激素阻断治疗。在倾向性评分匹配之后,1006名他汀类药物使用者和1006名非他汀类药物使用

Diabetic Med:澳大利亚成功实施糖尿病全国范围内的审核?

近日,国际杂志 《Diabetic Med》上在线发表一项关于澳大利亚成功实施糖尿病审核--澳大利亚国家糖尿病信息审计和基准(ANDIAB)倡议的研究。研究人员制定并实施了一项国家审计和基准计划,以描述在澳大利亚参加专科糖尿病护理患者的临床状况。 澳大利亚国家糖尿病信息审计和基准(ANDIAB)倡议是作为一项质量审核活动而建立的。从澳大利亚各地的专业糖尿病服务中收集关于人口统计学,临床,生物

Lancet:Albiglutide可降低心血管高风险的II糖尿病患者主要心血管事件风险

研究认为,GLP类似Albiglutide可降低II型糖尿病伴心血管疾病患者的主要心血管事件风险

Eur Respir J:持续气道正压对2型糖尿病合并阻塞性睡眠呼吸暂停患者视力的影响

与12个月以上的常规护理相比,采用CPAP治疗OSA并未改善2型糖尿病合并DMO患者的视力。

Crit Care:急性低氧呼吸衰竭患者糖尿病与急性呼吸窘迫综合征的相关性研究

由此可见,在一项针对AHRF患者的大型全球观察性研究中,未发现糖尿病与既往患有ARDS、ARDS发生发展或ARDS结局之间存在关联。

Diabetes Care:基于大规模中国人群彩色眼底照片的糖尿病视网膜病变自动深度学习算法

糖尿病视网膜病变(Diabetic retinopathy,DR)是糖尿病最常见的微血管并发症,是工作年龄成人不可逆视力丧失的主要原因。 在临床上,甚至有一部分患者的糖尿病是有了视网膜病变之后在眼科门诊发现自己得了糖尿病的。